Patrick Philibert

Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection

Chloe Orkin, Keikawus Arastéh, Miguel Górgolas Hernández-Mora et al. · New England Journal of Medicine · 2020 · 464 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · The Lancet · 2018 · 381 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

Antonella Castagna, Franco Maggiolo, Giovanni Penco et al. · The Journal of Infectious Diseases · 2014 · 329 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study

Chloe Orkin, Shinichi Oka, Patrick Philibert et al. · The Lancet HIV · 2021 · 177 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission

Antoine Chéret, Charline Bacchus-Souffan, Véronique Avettand-Fènoël et al. · Journal of Antimicrobial Chemotherapy · 2015 · 103 citations

Life Sciences, Cell Biology, Immunology +16